1-methylpseudouridine: metabolite from culture filtrates of Streptomyces platensis; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
1-methylpseudouridine : A methylpseudouridine in which the methyl group is located at position N-1 on the uracil ring. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 99543 |
| CHEBI ID | 19068 |
| SCHEMBL ID | 63879 |
| MeSH ID | M0061491 |
| Synonym |
|---|
| nsc-240023 |
| 13860-38-3 |
| 1-methylpseudouridine |
| 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1-methylpyrimidine-2,4-dione |
| n1-methyl-pseudouridine |
| 09rad4m6wf , |
| unii-09rad4m6wf |
| nsc 240023 |
| m(1)f |
| (1s)-1,4-anhydro-1-(1-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-d-ribitol |
| CHEBI:19068 |
| SCHEMBL63879 |
| uracil, 1-methyl-5-.beta.-d-ribofuranosyl- |
| n1-methylpseudouridine , |
| DTXSID50160724 |
| u-50228 |
| AKOS030241474 |
| 1-n-me-pseudouridine |
| 2,4(1h,3h)-pyrimidinedione, 1-methyl-5-.beta.-d-ribofuranosyl- |
| M3387 |
| u 50228 |
| 5-((2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1-methylpyrimidine-2,4(1h,3h)-dione |
| mfcd10687017 |
| 1-n-methyl-pseudouridine |
| Q27109108 |
| HY-112582 |
| CS-0047598 |
| BS-51848 |
| 1-methyl-pseudouridine |
| A903408 |
| 8IZ , |
| 5-[(2s,3r,4s,5r)-5-(hydroxymethyl)-3,4-bis(oxidanyl)oxolan-2-yl]-1-methyl-pyrimidine-2,4-dione |
| PD156923 |
| 1-methyl-5-beta-d-ribofuranosyl-2,4(1h,3h)-pyrimidinedione |
| m1psi |
| (1s)-1,4-anhydro-1-(1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)-d-ribitol |
| 1-methyl-5-beta-d-ribofuranosyluracil |
| BP-58832 |
| beta-1-methylpseudouridine |
| EX-A7845K |
| Class | Description |
|---|---|
| methylpseudouridine | A member of the class of pseudouridines that is pseudouridine substituted by a methyl group at unspecified position. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (23.08) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 4 (30.77) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||